Gilead Sciences (GILD) 92.99 $GILD
$1,000 Sovaldi now hepatitis treatment of choice
By RICARDO ALONSO-ZALDIVAR - AP - Tue Jul 29, 5:47PM CDT
WASHINGTON (AP) — The price is sky-high, but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.
Final Glance: Biotechnology companies
AP - Tue Jul 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.67% Yesterday
Comtex SmarTrend(R) - Tue Jul 29, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $91.60 to a high of $93.25. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $92.97 on volume of 14.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Gilead Sciences to Potentially Pullback after Yesterday's 1.67% Rise
Comtex SmarTrend(R) - Tue Jul 29, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $91.60 to a high of $93.25. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $92.97 on volume of 14.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Midday Glance: Biotechnology companies
AP - Tue Jul 29, 12:29PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Jul 29, 10:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Aetna Earnings Beat But Rising Medical Costs A Worry
at Investor's Business Daily - Tue Jul 29, 10:03AM CDT
Aetna gave its earnings guidance a booster shot following a strong second quarter aided by its acquisition of Coventry Health Care in 2013. The health insurer's earnings rose 11.2% to $1.69 a share, topping estimates for $1.60. Revenue jumped 25.3%...
Fairchild Semiconductor, E*Trade Financial, Gilead Sciences, Roche and Biogen Idec highlighted as Zacks Bull and Bear of the Day
PR Newswire - Tue Jul 29, 8:30AM CDT
Zacks Equity Research highlights Fairchild Semiconductor (Nasdaq:FCS -Free Report) as the Bull of the Day and E*Trade Financial (Nasdaq:ETFC -Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Gilead Sciences (Nasdaq:GILD -Free Report), Roche (OTC:RHHBY -Free Report) and Biogen Idec (Nasdaq:BIIB -Free Report).
Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.
Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:15PM CDT
Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) Imbruvica has been recommended for approval in the EU.
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
Amgen Shares Have the Right Prescription for Long-Term Growth
at The Street - Mon Jul 28, 11:06AM CDT
On the basis of improving cash flow and positive clinical trial data, these shares should reach $135 in the next six to 12 months.
Gilead Sciences (GILD) Approaches New Upside Target of $91.85
Comtex SmarTrend(R) - Mon Jul 28, 10:14AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $89.77 today and has reached the first level of resistance at $90.85. Investors may be interested in a cross of the next upside pivot targets of $91.85 and $93.93.
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Jul 28, 10:02AM CDT
Gilead Sciences (GILD) price target was raised to $127 by analysts at Maxim Group on Monday.
This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 26, 12:32PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
AbbVie Beats Earnings Views, Sees Slower Humira Gain
at Investor's Business Daily - Fri Jul 25, 10:46AM CDT
Big pharma AbbVie (ABBV) beat analysts' Q2 estimates as its lead drug Humira grew sharply, though the company said this would slow down and affirmed its full-year guidance. The stock fell fractionally in morning trading on the stock market today....
$1,000 Sovaldi now hepatitis treatment of choice
By RICARDO ALONSO-ZALDIVAR - AP - Tue Jul 29, 5:47PM CDT
WASHINGTON (AP) — The price is sky-high, but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.
Final Glance: Biotechnology companies
AP - Tue Jul 29, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Watch for Gilead Sciences to Potentially Pullback After Gaining 1.67% Yesterday
Comtex SmarTrend(R) - Tue Jul 29, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $91.60 to a high of $93.25. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $92.97 on volume of 14.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Gilead Sciences to Potentially Pullback after Yesterday's 1.67% Rise
Comtex SmarTrend(R) - Tue Jul 29, 3:40PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $91.60 to a high of $93.25. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $92.97 on volume of 14.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Midday Glance: Biotechnology companies
AP - Tue Jul 29, 12:29PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Early Glance: Biotechnology companies
AP - Tue Jul 29, 10:28AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Aetna Earnings Beat But Rising Medical Costs A Worry
at Investor's Business Daily - Tue Jul 29, 10:03AM CDT
Aetna gave its earnings guidance a booster shot following a strong second quarter aided by its acquisition of Coventry Health Care in 2013. The health insurer's earnings rose 11.2% to $1.69 a share, topping estimates for $1.60. Revenue jumped 25.3%...
Fairchild Semiconductor, E*Trade Financial, Gilead Sciences, Roche and Biogen Idec highlighted as Zacks Bull and Bear of the Day
PR Newswire - Tue Jul 29, 8:30AM CDT
Zacks Equity Research highlights Fairchild Semiconductor (Nasdaq:FCS -Free Report) as the Bull of the Day and E*Trade Financial (Nasdaq:ETFC -Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Gilead Sciences (Nasdaq:GILD -Free Report), Roche (OTC:RHHBY -Free Report) and Biogen Idec (Nasdaq:BIIB -Free Report).
Gilead's Oncology Drug Recommended for Approval in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:40PM CDT
Gilead's (GILD) Zydelig has been recommended for approval in the EU.
Pharmacyclics/Johnson & Johnson Drug Backed for EU Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 4:15PM CDT
Pharmacyclics (PCYC) and Johnson & Johnson's (JNJ) Imbruvica has been recommended for approval in the EU.
Jim Cramer Talks Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB) Stocks
at The Street - Mon Jul 28, 11:12AM CDT
TheStreet's Jim Cramer answers Twitter (TWTR) questions on Dollar Tree (DLTR), Apple (AAPL), Coach (COH) and Facebook (FB).
Amgen Shares Have the Right Prescription for Long-Term Growth
at The Street - Mon Jul 28, 11:06AM CDT
On the basis of improving cash flow and positive clinical trial data, these shares should reach $135 in the next six to 12 months.
Gilead Sciences (GILD) Approaches New Upside Target of $91.85
Comtex SmarTrend(R) - Mon Jul 28, 10:14AM CDT
Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $89.77 today and has reached the first level of resistance at $90.85. Investors may be interested in a cross of the next upside pivot targets of $91.85 and $93.93.
Why Gilead Sciences (GILD) Stock Is Up Today
at The Street - Mon Jul 28, 10:02AM CDT
Gilead Sciences (GILD) price target was raised to $127 by analysts at Maxim Group on Monday.
This Week in Biotech: Puma Sprints, Gilead Sweeps, and Inovio Hits the Mark
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 26, 12:32PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
AbbVie Beats Earnings Views, Sees Slower Humira Gain
at Investor's Business Daily - Fri Jul 25, 10:46AM CDT
Big pharma AbbVie (ABBV) beat analysts' Q2 estimates as its lead drug Humira grew sharply, though the company said this would slow down and affirmed its full-year guidance. The stock fell fractionally in morning trading on the stock market today....
